Polygenic risk scores for cervical HPV infection, neoplasia and cancer show potential for personalised screening: comparison of two methods.
Cervical cancer
Cervical intraepithelial neoplasia
HPV
Polygenic risk score
Screening
Journal
Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559
Informations de publication
Date de publication:
07 Dec 2023
07 Dec 2023
Historique:
received:
20
06
2023
accepted:
29
11
2023
medline:
7
12
2023
pubmed:
7
12
2023
entrez:
7
12
2023
Statut:
epublish
Résumé
The era of precision medicine requires the achievement of accurate risk assessment. Polygenic risk scores (PRSs) have strong potential for increasing the benefits of nationwide cancer screening programs. The current pool of evidence on the role of a PRS as a risk stratification model in actual practice and implementation is limited. To better understand the impact of possible method-induced variance, we constructed and validated two PRSs for cervical cancer (CC) using the Estonian Biobank female population (691 CC cases and 13,820 controls) and evaluated their utility in predicting incident cervical neoplasia (CIN), cancer, and human papillomavirus (HPV) infection using two methods (LDPred and BayesRR-RC). This study demonstrated that two genetic risk scores were significantly associated with CIN, CC, and HPV infection incidence. Independent of the method, we demonstrated that women with elevated PRS values reached the observed cumulative risk levels of CIN or CC much earlier. Our results indicated that the PRS-based discrimination rules could differ substantially when the PRSs contain similar predictive information. In summary, our analysis indicated that PRSs represent a personalized genetic component that could be an additional tool for cervical cancer risk stratification, and earlier detection of abnormalities provides invaluable information for those at high risk.
Identifiants
pubmed: 38057845
doi: 10.1186/s13027-023-00561-4
pii: 10.1186/s13027-023-00561-4
pmc: PMC10702115
doi:
Types de publication
Journal Article
Langues
eng
Pagination
82Subventions
Organisme : EEA Grants/Norway Grants
ID : EMP416
Organisme : Eesti Teadusagentuur
ID : PSG776, PRG1911
Organisme : Eesti Teadusagentuur
ID : PSG776, PRG1911
Organisme : Eesti Teadusagentuur
ID : PSG776, PRG1911
Organisme : European Regional Development Fund Project
ID : 2014-2020.4.01.15-0012 GENTRANSMED
Organisme : European Regional Development Fund Project
ID : 2014-2020.4.01.15-0012 GENTRANSMED
Organisme : European Regional Development Fund Project
ID : 2014-2020.4.01.15-0012 GENTRANSMED
Investigateurs
Andres Metspalu
(A)
Lili Milani
(L)
Tõnu Esko
(T)
Reedik Mägi
(R)
Mari Nelis
(M)
Georgi Hudjashov
(G)
Informations de copyright
© 2023. The Author(s).
Références
Int J Epidemiol. 2015 Aug;44(4):1137-47
pubmed: 24518929
Nat Commun. 2021 Nov 30;12(1):6972
pubmed: 34848700
Nat Commun. 2021 Apr 20;12(1):2337
pubmed: 33879782
Nat Genet. 2022 Jan;54(1):30-39
pubmed: 34931067
J Natl Cancer Inst Monogr. 2003;(31):20-8
pubmed: 12807941
BMC Cancer. 2019 Jun 10;19(1):557
pubmed: 31182048
NPJ Precis Oncol. 2022 May 30;6(1):32
pubmed: 35637246
Cancers (Basel). 2021 Oct 13;13(20):
pubmed: 34680286
Sex Transm Dis. 2014 Nov;41(11):660-4
pubmed: 25299412
J Pers Med. 2015 Apr 16;5(2):96-106
pubmed: 25894366
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9362-7
pubmed: 19474294
Eur J Hum Genet. 2017 Jun;25(7):869-876
pubmed: 28401899
PLoS Genet. 2017 Aug 14;13(8):e1006866
pubmed: 28806749
Int J Cancer. 2016 Jan 15;138(2):361-8
pubmed: 26238558
BMC Med. 2023 Jul 27;21(1):274
pubmed: 37501128